Your fact-checks will appear here
A condition that involves problems with memory or other mental functions that are greater than normal for a person's age but not severe enough to interfere significantly with daily life.
Clinical and preclinical literature describes repeated low-dose methylene blue (MB) as a candidate neuroprotective and memory‑enhancing agent via mitochondrial and anti‑oxidant actions, with human ima...
Randomized trials point to a small set of —most convincingly —showing measurable cognitive benefits in people with suspected mild cognitive impairment () or mild–moderate Alzheimer’s disease (AD), typ...
Randomized trials that reported in older adults with mild cognitive impairment () most commonly used daily phosphatidylserine (PS) doses on the order of ~300 mg, typically given as three 100 mg doses,...
Randomized controlled trials specifically testing honey for mild cognitive impairment (MCI) or Alzheimer’s disease do not exist in the published literature . Cinnamon has been evaluated in a tiny clin...
Randomized controlled trials (RCTs) and systematic reviews converge on a clear pattern: has produced cognitive benefits most consistently in people with mild cognitive impairment (), but large RCTs in...
Existing dementia drugs like donepezil produce small-to-moderate, short‑to‑medium term symptomatic benefits on cognition, global clinical state and daily function, but high‑quality evidence that they ...